NASDAQ$LGVN
Longeveron Inc-A · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced second quarter 2024 financial results and provided a business update.
Longeveron Inc. reported on the progress of its investigational cellular therapy candidate, Lomecel-B™, for Alzheimer’s disease and Hypoplastic Left Heart Syndrome (HLHS). The U.S. FDA granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease. The company believes it has sufficient capital to fund operations through the fourth quarter of 2025.
- Advanced Lomecel-B™ as a potential treatment for Alzheimer’s disease and Hypoplastic Left Heart Syndrome (HLHS).
- Received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for Lomecel-B™ in treating mild Alzheimer’s disease.
- Observed strong interest and support for the HLHS ELPIS II Phase 2b clinical trial, which has achieved 70% enrollment.
- Capital sufficient to fund the Company through the fourth quarter of 2025.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$468K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
Longeveron believes it has sufficient capital to fund the Company through the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+22.2%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | +4.3% | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro